Über das Unternehmen

Stemcentrx develops therapies that cure and significantly improve survival for cancer patients. It provides disease specific treatments that attack tumors at the roots. Brian Slingerland and Scott J. Dylla founded Stemcentrx in 2008, with its headquarters in South San Francisco in California. Stemcentrx operates as a subsidiary of AbbVie as of June 1, 2016.

US
Unbekannt
Nicht verifiziertes Unternehmen